07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

ATS907: Phase IIa started

Altheos began a 2-stage, single-blind, dose-ranging, U.S. Phase IIa trial of once- or twice-daily ATS907 eye drops for up to 28 days in about 210 patients with primary open-angle glaucoma and/or ocular hypertension. The first...
01:19 , Feb 10, 2012 |  BC Extra  |  Financial News

Altheos raises $12.5M, starts glaucoma trial

Altheos Inc. (South San Francisco, Calif.) raised an additional $12.5 million in a series A round and announced the start of a Phase IIa trial for ATS907 in patients with primary open angle glaucoma and/or...
07:00 , Apr 12, 2010 |  BioCentury  |  Strategy

Altheos Mines its Rho-lodex

After concluding that all the interesting new projects in the U.S. and Europe had been picked over, the founders of Altheos Inc. turned to Asia to find assets for in-licensing. Based on the strength of...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Company News

Altheos, Asahi Kasei Pharma deal

Asahi Kasei granted Altheos exclusive, worldwide rights, excluding Japan and Korea, to develop and commercialize ATS907 for all indications. ATS907, a Rho kinase inhibitor, is in preclinical development to treat glaucoma. The license also includes...
00:56 , Apr 6, 2010 |  BC Extra  |  Financial News

Altheos raises $20M, in-licenses glaucoma compound

Altheos Inc. (South San Francisco, Calif.) raised $20 million in a series A round on Monday and announced a deal with Asahi Kasei Pharma Corp. Asahi granted Altheos exclusive, worldwide rights, excluding Japan and Korea,...